GeoVax Completes Enrollment of Phase 2 Trial for Next-Generation COVID-19 Vaccine Booster

GeoVax Labs, Inc. announced that it has met the enrollment target for its Phase II clinical trial evaluating GEO-CM04S1 as a booster for healthy patients who have previously received the Pfizer or Moderna mRNA vaccine
[Geovax Labs, Inc.]
Press Release

Stay up-to-date with your field!

Subscribe for free weekly science newsletters.

Related News